Journal article · 2024 · Open access

Alzheimer's disease drug development pipeline: 2024

Jeffrey L. Cummings, Yadi Zhou, Garam Lee, Kate Zhong, Jorge Ramón Fonseca Cacho, Feixiong Cheng

Alzheimer s & Dementia Translational Research & Clinical Interventions, 10(2), e12465 · Published 1 April 2024 · DOI 10.1002/trc2.12465

Free PDFView at the publisherCite this paper

In brief

“Alzheimer's disease drug development pipeline: 2024” is a 2024 journal article by Jeffrey L. Cummings and 5 co-authors, published in Alzheimer s & Dementia Translational Research & Clinical Interventions. OpenAlex counts 800 citations as of 15 November 2026, which puts it in the top 7% of works published in 2024 by citations. It is open access under a CC BY-NC-ND licence: the full text is free to read at Alzheimer s & Dementia Translational Research & Clinical Interventions.

Citations
800
Most cited in
2025 (276)
Field-weighted impact
79.45
References
18
Authors
6

Abstract

INTRODUCTION New therapies to prevent or delay the onset of symptoms, slow progression, or improve cognitive and behavioral symptoms of Alzheimer's disease (AD) are needed. METHODS We interrogated clinicaltrials.gov including all clinical trials assessing pharmaceutical therapies for AD active in on January 1, 2024. We used the Common Alzheimer's Disease Research Ontology (CADRO) to classify the targets of therapies in the pipeline. RESULTS There are 164 trials assessing 127 drugs across the 2024 AD pipeline. There were 48 trials in Phase 3 testing 32 drugs, 90 trials in Phase 2 assessing 81 drugs, and 26 trials in Phase 1 testing 25 agents. Of the 164 trials, 34% ( N = 56) assess disease‐modifying biological agents, 41% ( N = 68) test disease‐modifying small molecule drugs, 10% ( N = 17) evaluate cognitive enhancing agents, and 14% ( N = 23) test drugs for the treatment of neuropsychiatric symptoms. DISCUSSION Compared to the 2023 pipeline, there are fewer trials (164 vs. 187), fewer drugs (127 vs. 141), fewer new chemical entities (88 vs. 101), and a similar number of repurposed agents (39 vs. 40). Highlights In the 2024 Alzheimer's disease drug development pipeline, there are 164 clinical trials assessing 127 drugs. The 2024 Alzheimer's disease drug development pipeline has contracted compared to the 2023 Alzheimer pipeline with fewer trials, fewer drugs, and fewer new chemical entities. Drugs in the Alzheimer's disease drug development pipeline target a wide array of targets; the most common processes targeted include neurotransmitter receptors, inflammation, amyloid, and synaptic plasticity. The total development time for a potential Alzheimer's disease therapy to progress from nonclinical studies to FDA review is approximately 13 years.

Cite this paper

Formatted from the catalogue record. Check names, capitals and page numbers against the paper before you submit.

APA 7

Cummings, J. L., Zhou, Y., Lee, G., Zhong, K., Cacho, J. R. F., & Cheng, F. (2024). Alzheimer's disease drug development pipeline: 2024. Alzheimer s & Dementia Translational Research & Clinical Interventions, 10(2), e12465. https://doi.org/10.1002/trc2.12465

MLA 9

Cummings, Jeffrey L., et al. “Alzheimer's disease drug development pipeline: 2024.” Alzheimer s & Dementia Translational Research & Clinical Interventions, vol. 10, no. 2, 2024, p. e12465. https://doi.org/10.1002/trc2.12465.

Chicago

Cummings, Jeffrey L., Yadi Zhou, Garam Lee, Kate Zhong, Jorge Ramón Fonseca Cacho, and Feixiong Cheng. 2024. “Alzheimer's disease drug development pipeline: 2024.” Alzheimer s & Dementia Translational Research & Clinical Interventions 10 (2): e12465. https://doi.org/10.1002/trc2.12465.

Harvard

Cummings, J. L. et al. (2024) ‘Alzheimer's disease drug development pipeline: 2024’, Alzheimer s & Dementia Translational Research & Clinical Interventions, 10(2), p. e12465. doi:10.1002/trc2.12465.

IEEE

J. L. Cummings, Y. Zhou, G. Lee, K. Zhong, J. R. F. Cacho, and F. Cheng, “Alzheimer's disease drug development pipeline: 2024,” Alzheimer s & Dementia Translational Research & Clinical Interventions, vol. 10, no. 2, p. e12465, 2024, doi: 10.1002/trc2.12465.

BibTeX

@article{cummings2024alzheimer,
  title     = {{Alzheimer's disease drug development pipeline: 2024}},
  author    = {Cummings, Jeffrey L. and Zhou, Yadi and Lee, Garam and Zhong, Kate and Cacho, Jorge Ramón Fonseca and Cheng, Feixiong},
  journal   = {Alzheimer s \& Dementia Translational Research \& Clinical Interventions},
  year      = {2024},
  volume    = {10},
  number    = {2},
  pages     = {e12465},
  doi       = {10.1002/trc2.12465},
  url       = {https://doi.org/10.1002/trc2.12465}
}

Download for a reference manager: BibTeX (.bib) · RIS for Zotero, Mendeley and EndNote (.ris)

Citations by year

YearCitationsShare of the best year
201822
201966
20202222
20215858
20227171
20235050
2024155155
2025276276
2026160160

Its field-weighted citation impact is 79.45: it has been cited 79.45 times as often as the average work of the same field, type and year (1.00 is the world average).

Topic and keywords

Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments

  • Alzheimer's disease
  • drug development pipeline
  • clinical trials
  • disease-modifying therapy
  • small molecule drugs
  • nootropic drugs
  • neuropsychiatric symptoms
  • drug repurposing

Work with this paper

Most-cited papers in Neuroscience

All highly cited Neuroscience papers

Questions about this paper

How do I cite this paper in APA style?

Cummings, J. L., Zhou, Y., Lee, G., Zhong, K., Cacho, J. R. F., & Cheng, F. (2024). Alzheimer's disease drug development pipeline: 2024. Alzheimer s & Dementia Translational Research & Clinical Interventions, 10(2), e12465. https://doi.org/10.1002/trc2.12465

How many times has this paper been cited?

800 times, according to OpenAlex on 15 November 2026. Google Scholar and Scopus count different sets of sources, so their numbers differ.

Is this paper free to read?

Yes. It is open access: read the free full text at Alzheimer s & Dementia Translational Research & Clinical Interventions.

Who wrote this paper?

Jeffrey L. Cummings, Yadi Zhou, Garam Lee, Kate Zhong, Jorge Ramón Fonseca Cacho, Feixiong Cheng.

What is the DOI of this paper?

10.1002/trc2.12465. The permanent link is https://doi.org/10.1002/trc2.12465.

Bibliographic data from OpenAlex (CC0), last checked 15 November 2026. ResearchGuru does not host this paper; the links go to the publisher or the repository that does.